Akouos, Inc. AKUS
We take great care to ensure that the data presented and summarized in this overview for Akouos, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in AKUS
Top Purchases
Top Sells
About AKUS
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Insider Transactions at AKUS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 30
2022
|
New Enterprise Associates 16, L.P. > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
4,294,207
-100.0%
|
-
|
|
Nov 30
2022
|
Forest Baskett > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,294,207
-100.0%
|
-
|
|
Nov 30
2022
|
Ali Behbahani > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,294,207
-100.0%
|
-
|
|
Nov 30
2022
|
Carmen Chang > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,294,207
-100.0%
|
-
|
|
Nov 30
2022
|
Anthony A. Florence Jr. > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,294,207
-100.0%
|
-
|
|
Nov 30
2022
|
Mohamad Makhzoumi > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,294,207
-100.0%
|
-
|
|
Nov 30
2022
|
Scott D Sandell > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,294,207
-100.0%
|
-
|
|
Nov 30
2022
|
Peter W. Sonsini > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,294,207
-100.0%
|
-
|
|
Nov 30
2022
|
Paul Edward Walker > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,294,207
-100.0%
|
-
|
|
Nov 30
2022
|
Michael John Mc Kenna Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
82,385
-100.0%
|
-
|
|
Nov 30
2022
|
Kush Parmar Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,135,786
-100.0%
|
-
|
|
Nov 30
2022
|
Heather Preston Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,882
-100.0%
|
-
|
|
Nov 30
2022
|
Emmanuel Simons Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
272,582
-100.0%
|
-
|
|
Nov 30
2022
|
Arthur Tzianabos Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
26,930
-100.0%
|
-
|
|
Nov 30
2022
|
Jennifer Anne Wellman CHIEF OPERATING OFFICER |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
12,338
-100.0%
|
-
|
|
Nov 30
2022
|
5 Am Ventures V, L.P. > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,135,786
-100.0%
|
-
|
|
Nov 30
2022
|
Kearny Acquisition Corp > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
29,992,668
+100.0%
|
$359,912,016
$12.5 P/Share
|
|
Dec 29
2020
|
5 Am Ventures V, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
470,000
-10.2%
|
$8,460,000
$18.0 P/Share
|
|
Dec 29
2020
|
Kush Parmar Director |
SELL
Open market or private sale
|
Indirect |
470,000
-10.2%
|
$8,460,000
$18.0 P/Share
|
|
Jun 30
2020
|
Eco R1 Capital, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,176,000
+37.31%
|
$19,992,000
$17.0 P/Share
|